Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer announces agreement to lower medicine prices for HIV patients

Pfizer announces agreement to lower medicine prices for HIV patients

7th August 2009

Pfizer has announced an agreement to facilitate the provision of more affordable treatment for patients receiving second-line antiretroviral (ARV) therapy for HIV and Aids in the developing world.

The company committed to improving access to treatment through a 60 per cent decrease in price for a tuberculosis drug for patients taking second-line HIV and Aids medications.

The agreement has been made with the Clinton HIV/Aids Initiative.

Meanwhile, Matrix, a Mylan company, has also announced a reduction in price for a once-daily four-drug combination for the management of HIV and Aids as part of a deal with the former US president’s organisation.

Jeffrey Kindler, chairman and chief executive of Pfizer, said: “Pfizer is pursuing numerous global health projects like this one with the Clinton HIV/Aids Initiative to find new ways to connect people to the medicines they need.”

In other news, Pfizer and Medivation recently announced the initiation of a new phase III trial into the safety and efficacy of its investigational drug dimebon (latrepirdine) in patients with Huntington disease.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.